Points to consider for the treatment of immune mediated inflammatory diseases with Janus kinase inhibitors (JAKi): a consensus statement

Expert committee review the five agents licensed in the UK and summarise current understanding of JAKi use. A total of 26 points for consideration are provided; addressing indications, dose, contraindications, pre-treatment screening, follow-up examinations and adverse events.

Annals of the Rheumatic Diseases